Boston Scientific, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Joanne Wuensch from Citi reiterated a Buy rating on the stock and has a $130.00 price target.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Joanne Wuensch has given his Buy rating due to a combination of factors tied to Boston Scientific’s growth outlook and execution. Management reaffirmed its long-range plan, underscoring expectations for double‑digit organic revenue expansion, robust double‑digit adjusted EPS growth, and strong free cash flow conversion. The company also highlighted a rapidly expanding electrophysiology market and expressed confidence in its near‑term performance despite some softer industry data, pointing to recently approved technologies and new site-of-care opportunities as incremental growth drivers.
Wuensch also notes additional catalysts beyond electrophysiology that support the positive stance. These include anticipated growth in Watchman procedures as combined treatments become more common, expanding clinical indications for the Therasphere platform, forthcoming trial results, and continued momentum in the intravascular lithotripsy portfolio. Collectively, these elements suggest a diversified set of growth engines and sustained operational execution, underpinning her decision to reiterate a Buy rating on Boston Scientific shares.